Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCGR3B | O75015 | 1/20 | 0.82 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.82 |
| ▸ | FCGR2A | P12318 | 1/20 | 0.82 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.69 |
| ▸ | KCNH3 | Q9ULD8 | 10/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | GBA1 | P04062 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3200004 | 0.99 | FCGR3B (0.80) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13421296 | 0.93 | FCGR3B (0.96) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13917176 | 0.90 | FCGR3B (1.00) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13421038 | 0.90 | FCGR3B (0.78) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13421034 | 0.89 | GBA1 (0.70) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13420997 | 0.88 | RECQL (0.71) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13421032 | 0.87 | FCGR3B (0.71) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL3203902 | 0.87 | RECQL (0.69) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| Benzene SCHEMBL3952455 | 0.85 | FCGR3B (0.65) | FCGR3BFCGR1AFCGR2ARECQLMCL1 | |
| SCHEMBL13917185 | 0.84 | FCGR3B (0.89) | FCGR3BFCGR1AFCGR2ARECQLMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687297-B1 | TRIAZINE DIMERS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | PROMETIC BIOSCIENCES INC (CA) | 2014-06-18 | — | — | EP | disclosed |
| US-7683061-B2 | Triazine dimers for the treatment of autoimmune diseases | PROMETIC BIOSCIENCES INC. (CA) | 2010-03-23 | — | — | US | disclosed |
| US-7683061-B2 | Triazine dimers for the treatment of autoimmune diseases | PROMETIC BIOSCIENCES INC. (CA) | 2010-03-23 | — | — | US | disclosed |
| US-20070149528-A1 | Triazine dimers for the treatment of autoimmune diseases | PROMETIC PHARMA SMT LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| US-20070149528-A1 | Triazine dimers for the treatment of autoimmune diseases | PROMETIC PHARMA SMT LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149528-A1 | Triazine dimers for the treatment of autoimmune diseases | SSB, TLR5, ICOS | FCGR3B 19/4885FCGR1A 18/4885FCGR2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.